Acupuncture based on specific acupoint theory for the reduction of atrial fibrillation burden: a randomized controlled pilot trial

注册号:

Registration number:

ITMCTR2000003095

最近更新日期:

Date of Last Refreshed on:

2020-03-07

注册时间:

Date of Registration:

2020-03-07

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

特定穴配穴减少房颤发作时间的随机对照临床预试验

Public title:

Acupuncture based on specific acupoint theory for the reduction of atrial fibrillation burden: a randomized controlled pilot trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

特定穴配穴减少房颤发作时间的随机对照临床预试验

Scientific title:

Acupuncture based on specific acupoint theory for the reduction of atrial fibrillation burden: a randomized controlled pilot trial

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

ChiCTR2000030576 ; ChiMCTR2000003095

申请注册联系人:

林滢

研究负责人:

刘存志

Applicant:

Ying Lin

Study leader:

Cunzhi Liu

申请注册联系人电话:

Applicant telephone:

+86 15140133056

研究负责人电话:

Study leader's telephone:

+86 010-53912201

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

linyingbucm@163.com

研究负责人电子邮件:

Study leader's E-mail:

lcz623780@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

北京市朝阳区北三环东路11号

研究负责人通讯地址:

北京市朝阳区北三环东路11号

Applicant address:

11 North Third Ring Road East, Chaoyang District, Beijing

Study leader's address:

11 North Third Ring Road East, Chaoyang District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

北京中医药大学针灸推拿学院

Applicant's institution:

School of Acupuncture-Moxibustion and Tuina, Beijing University of Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

2020BZHYLL0106

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

北京中医药大学伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2020/2/28 0:00:00

伦理委员会联系人:

秦玲玲

Contact Name of the ethic committee:

Lingling Qin

伦理委员会联系地址:

北京市朝阳区北三环东路11号

Contact Address of the ethic committee:

11 North Third Ring Road East, Chaoyang District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 64286491

伦理委员会联系人邮箱:

Contact email of the ethic committee:

15201484725@126.com

研究实施负责(组长)单位:

北京中医药大学

Primary sponsor:

Beijing University of Chinese Medicine

研究实施负责(组长)单位地址:

北京市朝阳区北三环东路11号

Primary sponsor's address:

11 North Third Ring Road East, Chaoyang District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

经费或物资来源:

国家重点研发计划中医药现代化研究重点专项(项目编号:2019YFC1712100)

Source(s) of funding:

National Key R&D Program of China (Project Number: 2019YFC1712100)

研究疾病:

房颤

研究疾病代码:

Target disease:

Atrial fibrillation

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

评价针灸减少房颤发作时间的有效性和安全性。

Objectives of Study:

To evaluate the efficacy and safety of acupuncture in reducing atrial fibrillation burden.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

1. 持续性房颤(房颤持续时间<3年); 2. 18-75岁男女不限; 3. 术前6个月内未接受针灸治疗者;

Inclusion criteria

1. Persistent AF lasting no more than 3 years; 2. Age between 18 and 75 years old (male or female); 3. No acupuncture treatment within the previous 6 months.

排除标准:

1. 严重心力衰竭(纽约心功能分级,New York Heart Association (NYHA)III级或IV级); 2. 超声心动图:左心室射血分数<40%,左房直径>5.0cm; 3. 有严重肺、肝、肾疾病或其它严重原发疾病; 4. 皮肤对心电监测电极片过敏者; 5. 预期寿命<1年者。

Exclusion criteria:

1. Severe heart failure (New York Heart Association(NYHA)class III or IV); 2. Echocardiographic parameters: left ventricular ejection fraction < 40%, left atrium diameter > 5.0cm; 3. Severe lung, liver, kidney disease or other serious primary diseases; 4. Skin allergy to ECG monitoring electrode patch. 5. The estimated life expectancy of < 1 year.

研究实施时间:

Study execute time:

From 2020-03-30

To      2021-01-01

征募观察对象时间:

Recruiting time:

From 2020-04-15

To      2020-10-31

干预措施:

Interventions:

组别:

非经非穴组

样本量:

20

Group:

Non-acupoints group

Sample size:

干预措施:

针刺非穴,前6周每周2次,后6周每周1次

干预措施代码:

Intervention:

Twice per week for weeks 1-6 and once per week for weeks 7-12

Intervention code:

组别:

特定穴配穴组

样本量:

20

Group:

Specific acupionts group

Sample size:

干预措施:

针刺特定穴,前6周每周2次,后6周每周1次

干预措施代码:

Intervention:

Twice per week for weeks 1-6 and once per week for weeks 7-12

Intervention code:

组别:

非特定穴配穴组

样本量:

20

Group:

Non-specific acupoints group

Sample size:

干预措施:

针刺非特定穴,前6周每周2次,后6周每周1次

干预措施代码:

Intervention:

Twice per week for weeks 1-6 and once per week for weeks 7-12

Intervention code:

样本总量 Total sample size : 60

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

江苏省

市(区县):

南京市

Country:

China

Province:

Jiangsu

City:

Nanjing

单位(医院):

江苏省人民医院

单位级别:

三级甲等

Institution/hospital:

Jiangsu Province Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京大学人民医院

单位级别:

三级甲等

Institution/hospital:

Peking University People's Hospital

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

北京中医药大学东直门医院

单位级别:

三级甲等

Institution/hospital:

Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

天津

市(区县):

Country:

China

Province:

Tianjin

City:

单位(医院):

天津中医药大学第一附属医院

单位级别:

三级甲等

Institution/hospital:

The First Affiliated Hospital of Nanjing Medical University; Tianjin University of Traditional Chinese Medicine

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

再次消融患者比例

指标类型:

次要指标

Outcome:

Rate of repeat catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

患者因心律失常而住院的次数

指标类型:

次要指标

Outcome:

Number of hospitalizations related to arrhythmia

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

心率变异性

指标类型:

次要指标

Outcome:

Heart rate variability

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

针刺治疗的可信度/期望评价

指标类型:

次要指标

Outcome:

Evaluation of the reliability and expectation of acupuncture therapy

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后3个月内电复律的次数

指标类型:

次要指标

Outcome:

Number of electrical cardioversion within 3 months after catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

盲法评价

指标类型:

次要指标

Outcome:

Blind evaluation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

房颤特异性生活质量量表AFEQT量表

指标类型:

次要指标

Outcome:

AFEQT scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后3个月的房颤发作时间百分比

指标类型:

次要指标

Outcome:

Atrial fibrillation burden at 3 months after catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后房颤的复发

指标类型:

次要指标

Outcome:

Recurrence of atrial fibrillation after catheter ablation

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

导管消融术后6个月的房颤发作时间百分比

指标类型:

主要指标

Outcome:

Atrial fibrillation burden at 6 months after catheter ablation

Type:

Primary indicator

测量时间点:

导管消融术后第6 个月

测量方法:

Measure time point of outcome:

The 6th month after catheter ablation

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它

说明

Fate of sample 

Others

Note:

征募研究对象情况:

正在进行

Recruiting

年龄范围:

最小 18
Min age years
最大 75
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

采用区组随机,随机序列由一位专业的统计学家用SAS 9.3软件产生,

Randomization Procedure (please state who generates the random number sequence and by what method):

The blocked randomization sequence was prepared by a professional statistician with the SAS 9.3 software,

盲法:

对受试者、结局评价者、数据统计分析者隐藏组别信息。

Blinding:

Blind method for participants, outcome assessors and statisticians.

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成后6个月内,通过中国临床试验注册中心的ResMan平台进行原始数据的共享(http://www.medresman.org.cn.)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months after the trial complete, we will share IPD based on the ResMan platform (http://www.medresman.org.cn.)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

通过纸质CRF表格记录元数据,再由两人交叉核对将数据转录到epidata建立的数据库。数据管理由专人负责。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The records of metadata are recorded through a CRF form, and then cross-checked and transcribed to an electronic database file based on Epidata software. All the data management is handled by an independent person.

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above